The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Lung Cancer Diagnosis and Therapeutics Market Research Report 2025

Global Lung Cancer Diagnosis and Therapeutics Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1893118

No of Pages : 93

Ask Your Query
Synopsis
The global Lung Cancer Diagnosis and Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Lung Cancer Diagnosis and Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Lung Cancer Diagnosis and Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Lung Cancer Diagnosis and Therapeutics in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Lung Cancer Diagnosis and Therapeutics include AstraZeneca, Eli Lilly, Sanofi, ArQule, Daiichi Sankyo, Celgene, Merck, Pfizer and Boehringer Ingelheim, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Lung Cancer Diagnosis and Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lung Cancer Diagnosis and Therapeutics.
Report Scope
The Lung Cancer Diagnosis and Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lung Cancer Diagnosis and Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lung Cancer Diagnosis and Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Eli Lilly
Sanofi
ArQule
Daiichi Sankyo
Celgene
Merck
Pfizer
Boehringer Ingelheim
Roche
Genentech
GSK
Pharmacyclics
Novartis
Bayer
Bristol-Myers Squibb
Eisai
AbbVie
Segment by Type
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Segment by Application
Hospitals
Cancer Research Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Lung Cancer Diagnosis and Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lung Cancer Diagnosis and Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Non-Small Cell Lung Cancer
1.2.3 Small Cell Lung Cancer
1.3 Market by Application
1.3.1 Global Lung Cancer Diagnosis and Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Cancer Research Centers
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Lung Cancer Diagnosis and Therapeutics Market Perspective (2019-2030)
2.2 Lung Cancer Diagnosis and Therapeutics Growth Trends by Region
2.2.1 Global Lung Cancer Diagnosis and Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Lung Cancer Diagnosis and Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Lung Cancer Diagnosis and Therapeutics Market Dynamics
2.3.1 Lung Cancer Diagnosis and Therapeutics Industry Trends
2.3.2 Lung Cancer Diagnosis and Therapeutics Market Drivers
2.3.3 Lung Cancer Diagnosis and Therapeutics Market Challenges
2.3.4 Lung Cancer Diagnosis and Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lung Cancer Diagnosis and Therapeutics Players by Revenue
3.1.1 Global Top Lung Cancer Diagnosis and Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Lung Cancer Diagnosis and Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Lung Cancer Diagnosis and Therapeutics Revenue
3.4 Global Lung Cancer Diagnosis and Therapeutics Market Concentration Ratio
3.4.1 Global Lung Cancer Diagnosis and Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lung Cancer Diagnosis and Therapeutics Revenue in 2023
3.5 Lung Cancer Diagnosis and Therapeutics Key Players Head office and Area Served
3.6 Key Players Lung Cancer Diagnosis and Therapeutics Product Solution and Service
3.7 Date of Enter into Lung Cancer Diagnosis and Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Lung Cancer Diagnosis and Therapeutics Breakdown Data by Type
4.1 Global Lung Cancer Diagnosis and Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Type (2025-2030)
5 Lung Cancer Diagnosis and Therapeutics Breakdown Data by Application
5.1 Global Lung Cancer Diagnosis and Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Lung Cancer Diagnosis and Therapeutics Market Size (2019-2030)
6.2 North America Lung Cancer Diagnosis and Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2019-2024)
6.4 North America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Lung Cancer Diagnosis and Therapeutics Market Size (2019-2030)
7.2 Europe Lung Cancer Diagnosis and Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Lung Cancer Diagnosis and Therapeutics Market Size by Country (2019-2024)
7.4 Europe Lung Cancer Diagnosis and Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Lung Cancer Diagnosis and Therapeutics Market Size (2019-2030)
9.2 Latin America Lung Cancer Diagnosis and Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lung Cancer Diagnosis and Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Lung Cancer Diagnosis and Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Lung Cancer Diagnosis and Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Lung Cancer Diagnosis and Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Lung Cancer Diagnosis and Therapeutics Introduction
11.1.4 AstraZeneca Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.1.5 AstraZeneca Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Detail
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Lung Cancer Diagnosis and Therapeutics Introduction
11.2.4 Eli Lilly Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.2.5 Eli Lilly Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Lung Cancer Diagnosis and Therapeutics Introduction
11.3.4 Sanofi Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.3.5 Sanofi Recent Development
11.4 ArQule
11.4.1 ArQule Company Detail
11.4.2 ArQule Business Overview
11.4.3 ArQule Lung Cancer Diagnosis and Therapeutics Introduction
11.4.4 ArQule Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.4.5 ArQule Recent Development
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Company Detail
11.5.2 Daiichi Sankyo Business Overview
11.5.3 Daiichi Sankyo Lung Cancer Diagnosis and Therapeutics Introduction
11.5.4 Daiichi Sankyo Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.5.5 Daiichi Sankyo Recent Development
11.6 Celgene
11.6.1 Celgene Company Detail
11.6.2 Celgene Business Overview
11.6.3 Celgene Lung Cancer Diagnosis and Therapeutics Introduction
11.6.4 Celgene Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.6.5 Celgene Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Lung Cancer Diagnosis and Therapeutics Introduction
11.7.4 Merck Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.7.5 Merck Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Lung Cancer Diagnosis and Therapeutics Introduction
11.8.4 Pfizer Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.8.5 Pfizer Recent Development
11.9 Boehringer Ingelheim
11.9.1 Boehringer Ingelheim Company Detail
11.9.2 Boehringer Ingelheim Business Overview
11.9.3 Boehringer Ingelheim Lung Cancer Diagnosis and Therapeutics Introduction
11.9.4 Boehringer Ingelheim Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.9.5 Boehringer Ingelheim Recent Development
11.10 Roche
11.10.1 Roche Company Detail
11.10.2 Roche Business Overview
11.10.3 Roche Lung Cancer Diagnosis and Therapeutics Introduction
11.10.4 Roche Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.10.5 Roche Recent Development
11.11 Genentech
11.11.1 Genentech Company Detail
11.11.2 Genentech Business Overview
11.11.3 Genentech Lung Cancer Diagnosis and Therapeutics Introduction
11.11.4 Genentech Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.11.5 Genentech Recent Development
11.12 GSK
11.12.1 GSK Company Detail
11.12.2 GSK Business Overview
11.12.3 GSK Lung Cancer Diagnosis and Therapeutics Introduction
11.12.4 GSK Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.12.5 GSK Recent Development
11.13 Pharmacyclics
11.13.1 Pharmacyclics Company Detail
11.13.2 Pharmacyclics Business Overview
11.13.3 Pharmacyclics Lung Cancer Diagnosis and Therapeutics Introduction
11.13.4 Pharmacyclics Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.13.5 Pharmacyclics Recent Development
11.14 Novartis
11.14.1 Novartis Company Detail
11.14.2 Novartis Business Overview
11.14.3 Novartis Lung Cancer Diagnosis and Therapeutics Introduction
11.14.4 Novartis Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.14.5 Novartis Recent Development
11.15 Bayer
11.15.1 Bayer Company Detail
11.15.2 Bayer Business Overview
11.15.3 Bayer Lung Cancer Diagnosis and Therapeutics Introduction
11.15.4 Bayer Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.15.5 Bayer Recent Development
11.16 Bristol-Myers Squibb
11.16.1 Bristol-Myers Squibb Company Detail
11.16.2 Bristol-Myers Squibb Business Overview
11.16.3 Bristol-Myers Squibb Lung Cancer Diagnosis and Therapeutics Introduction
11.16.4 Bristol-Myers Squibb Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.16.5 Bristol-Myers Squibb Recent Development
11.17 Eisai
11.17.1 Eisai Company Detail
11.17.2 Eisai Business Overview
11.17.3 Eisai Lung Cancer Diagnosis and Therapeutics Introduction
11.17.4 Eisai Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.17.5 Eisai Recent Development
11.18 AbbVie
11.18.1 AbbVie Company Detail
11.18.2 AbbVie Business Overview
11.18.3 AbbVie Lung Cancer Diagnosis and Therapeutics Introduction
11.18.4 AbbVie Revenue in Lung Cancer Diagnosis and Therapeutics Business (2019-2024)
11.18.5 AbbVie Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock